<ddi:DDIInstance xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="ddi:instance:3_3 http://ddialliance.org/Specification/DDI-Lifecycle/3.3/XMLSchema/instance.xsd" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ddi="ddi:instance:3_3" xmlns:r="ddi:reusable:3_3" xmlns:s="ddi:studyunit:3_3" xmlns:d="ddi:datacollection:3_3" xmlns:a="ddi:archive:3_3" xmlns:c="ddi:conceptualcomponent:3_3" xmlns:cm="ddi:comparative:3_3" xmlns:g="ddi:group:3_3" xmlns:l="ddi:logicalproduct:3_3" xmlns:p="ddi:physicaldataproduct:3_3" xmlns:pi="ddi:physicalinstance:3_3" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace" isMaintainable="true" scopeOfUniqueness="Agency">
  <r:URN>urn:ddi:se.researchdata:snd1065-1:1.0</r:URN>
  <r:Agency>SND</r:Agency>
  <r:ID>snd1065-1</r:ID>
  <r:Version>1.0</r:Version>
  <g:ResourcePackage>
    <r:URN>urn:ddi:se.researchdata:snd1065-1.ResourcePackage:2.0</r:URN>
    <r:OtherMaterialScheme>
      <r:URN>urn:ddi:se.researchdata:snd1065-1.OtherMaterialScheme:2.0</r:URN>
    </r:OtherMaterialScheme>
    <a:OrganizationScheme>
      <r:URN>urn:ddi:se.researchdata:snd1065-1.OrganizationScheme-0:2.0</r:URN>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:snd1065-1.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>College of Health Science, School of Public Health, Makerere University</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Fredrick</a:FirstGiven>
            <a:LastFamily>Makumbi</a:LastFamily>
            <a:FullName>
              <r:String>Fredrick Makumbi</r:String>
            </a:FullName>
          </a:IndividualName>
        </a:IndividualIdentification>
      </a:Individual>
    </a:OrganizationScheme>
  </g:ResourcePackage>
  <s:StudyUnit>
    <r:URN>urn:ddi:se.researchdata:snd1065-1.StudyUnit:2.0</r:URN>
    <r:UserID typeOfUserID="datasetIdentifier">snd1065-1</r:UserID>
    <r:Citation>
      <r:Title>
        <r:String xml:lang="sv">Data for: Prevalence of protective tetanus antibodies and immunological response following tetanus toxoid vaccination among men seeking medical circumcision services in Uganda</r:String>
        <r:String xml:lang="en">Data for: Prevalence of protective tetanus antibodies and immunological response following tetanus toxoid vaccination among men seeking medical circumcision services in Uganda</r:String>
      </r:Title>
      <r:Creator>
        <r:CreatorReference>
          <r:URN>urn:ddi:se.researchdata:snd1065-1.Individual-0:2.0</r:URN>
          <r:TypeOfObject>Individual</r:TypeOfObject>
        </r:CreatorReference>
      </r:Creator>
      <r:Publisher>
        <r:PublisherName>
          <r:String xml:lang="sv">Uganda Ministry of Health, AIDS Control Program</r:String>
          <r:String xml:lang="en">Uganda Ministry of Health, AIDS Control Program</r:String>
        </r:PublisherName>
      </r:Publisher>
      <r:Publisher>
        <r:PublisherName>
          <r:String xml:lang="sv">Uganda Ministry of Health, AIDS Control Program</r:String>
          <r:String xml:lang="en">Uganda Ministry of Health, AIDS Control Program</r:String>
        </r:PublisherName>
      </r:Publisher>
      <r:PublicationDate>
        <r:SimpleDate>2019-01-14</r:SimpleDate>
      </r:PublicationDate>
      <r:InternationalIdentifier>
        <r:IdentifierContent>10.5878/2vmc-5511</r:IdentifierContent>
        <r:ManagingAgency controlledVocabularyAgencyName="DOI">DOI</r:ManagingAgency>
      </r:InternationalIdentifier>
    </r:Citation>
    <r:Abstract>
      <r:Content xml:lang="sv">Introduction:  Tetanus infection associated with men who had male circumcision has been reported in East Africa, suggesting a need for tetanus toxoid-containing vaccines (TTCV). 
Objective: To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision.
Methods: We enrolled 620 consenting men who completed a questionnaire and received TTCV at enrollment (day 0) prior to circumcision on day 28.  Blood samples were obtained at day 0 from all enrollees and on days 14, 28 and 42 from a random sample of 237 participants. Tetanus toxoid (TT) IgG antibody levels were assayed using EUROIMMUN. Analyses included prevalence of TT antibodies at enrollment and used a mixed effects model to determine the immunological response. 
Results: Mean age was 21.4 years, 65.2% had knowledge of tetanus, 56.6% knew how tetanus was contracted, 22.8% reported ever receipt of TTCV, and 16.8% had current/recently healed wounds.  Insufficient tetanus immunity was 57.1% at enrollment, 7.2% at day 14, 3.8% at day 28, and 0% at day 42.  Antibody concentration was 0.44IU/ml (CI 0.35-0.53) on day 0, 3.86IU/ml (CI 3.60-4.11) on day 14, 4.05IU/ml (CI 3.81-4.29) on day 28, and 4.48IU/ml (CI 4.28-4.68) on day 42. TT antibodies increased by 0.24IU/ml (CI 0.23, 0.26) between days 0 and 14 and by 0.023IU/ml (CI 0.015, 0.031) between days 14 and 42 days. Immunological response was poorer in HIV-infected clients and men aged 35+ years. 
Conclusion: Insufficient immunity was common prior to TTCV, and a protective immunological response was achieved by day 14. Circumcision may safely be provided 14 days after vaccination in HIV-uninfected men aged less than 35 years.

Syfte:

To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision.

Observations: 1,217 variables: 14 size: 116,832 Social demographics, TT antibody concentration, interpretation of concentration, participant identification variable</r:Content>
      <r:Content xml:lang="en">Introduction:  Tetanus infection associated with men who had male circumcision has been reported in East Africa, suggesting a need for tetanus toxoid-containing vaccines (TTCV). 
Objective: To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision.
Methods: We enrolled 620 consenting men who completed a questionnaire and received TTCV at enrollment (day 0) prior to circumcision on day 28.  Blood samples were obtained at day 0 from all enrollees and on days 14, 28 and 42 from a random sample of 237 participants. Tetanus toxoid (TT) IgG antibody levels were assayed using EUROIMMUN. Analyses included prevalence of TT antibodies at enrollment and used a mixed effects model to determine the immunological response. 
Results: Mean age was 21.4 years, 65.2% had knowledge of tetanus, 56.6% knew how tetanus was contracted, 22.8% reported ever receipt of TTCV, and 16.8% had current/recently healed wounds.  Insufficient tetanus immunity was 57.1% at enrollment, 7.2% at day 14, 3.8% at day 28, and 0% at day 42.  Antibody concentration was 0.44IU/ml (CI 0.35-0.53) on day 0, 3.86IU/ml (CI 3.60-4.11) on day 14, 4.05IU/ml (CI 3.81-4.29) on day 28, and 4.48IU/ml (CI 4.28-4.68) on day 42. TT antibodies increased by 0.24IU/ml (CI 0.23, 0.26) between days 0 and 14 and by 0.023IU/ml (CI 0.015, 0.031) between days 14 and 42 days. Immunological response was poorer in HIV-infected clients and men aged 35+ years. 
Conclusion: Insufficient immunity was common prior to TTCV, and a protective immunological response was achieved by day 14. Circumcision may safely be provided 14 days after vaccination in HIV-uninfected men aged less than 35 years.

Purpose:

To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision.

Observations: 1,217 variables: 14 size: 116,832 Social demographics, TT antibody concentration, interpretation of concentration, participant identification variable</r:Content>
    </r:Abstract>
    <r:Coverage>
      <r:TopicalCoverage>
        <r:URN>urn:ddi:se.researchdata:snd1065-1.TopicalCoverage:2.0</r:URN>
        <r:Subject xml:lang="en" controlledVocabularyID="Health" controlledVocabularyName="CESSDA Topic Classification">HEALTH</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="Health" controlledVocabularyName="CESSDA Topic Classification">HÄLSA</r:Subject>
        <r:Subject xml:lang="en" controlledVocabularyID="3" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Medical and Health Sciences</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="3" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Medicin och hälsovetenskap</r:Subject>
        <r:Keyword xml:lang="en" controlledVocabularyID="D013745" controlledVocabularyName="MeSH">Tetanus Toxoid</r:Keyword>
        <r:Keyword xml:lang="sv" controlledVocabularyID="D013745" controlledVocabularyName="MeSH">Stelkrampsvaccin</r:Keyword>
      </r:TopicalCoverage>
      <r:SpatialCoverage>
        <r:URN>urn:ddi:se.researchdata:snd1065-1.SpatialCoverage:2.0</r:URN>
        <r:Description>
          <r:Content xml:lang="en">13 sites in the 5 geographical regions (North, Western, Eastern Central and Kampala</r:Content>
        </r:Description>
        <r:CountryCode>UG</r:CountryCode>
      </r:SpatialCoverage>
    </r:Coverage>
    <d:DataCollection>
      <r:URN>urn:ddi:se.researchdata:snd1065-1.DataCollection:2.0</r:URN>
      <d:CollectionEvent>
        <r:URN>urn:ddi:se.researchdata:snd1065-1.CollectionEvent:2.0</r:URN>
        <d:DataCollectionDate>
          <r:StartDate>2016-01-10</r:StartDate>
          <r:EndDate>2016-11-02</r:EndDate>
        </d:DataCollectionDate>
        <d:ModeOfCollection>
          <r:URN>urn:ddi:se.researchdata:snd1065-1.CollectionEvent-0-ModeOfCollectionType:2.0</r:URN>
          <d:TypeOfModeOfCollection>Interview</d:TypeOfModeOfCollection>
          <r:Description>
            <r:Content xml:lang="en">Interview</r:Content>
            <r:Content xml:lang="sv">Intervju</r:Content>
          </r:Description>
        </d:ModeOfCollection>
      </d:CollectionEvent>
    </d:DataCollection>
    <d:DataCollection>
      <r:URN>urn:ddi:se.researchdata:snd1065-1.DataCollection:2.0</r:URN>
      <d:CollectionEvent>
        <r:URN>urn:ddi:se.researchdata:snd1065-1.CollectionEvent:2.0</r:URN>
        <d:DataCollectionDate>
          <r:StartDate>2016-01-10</r:StartDate>
          <r:EndDate>2016-11-02</r:EndDate>
        </d:DataCollectionDate>
        <d:ModeOfCollection>
          <r:URN>urn:ddi:se.researchdata:snd1065-1.CollectionEvent-0-ModeOfCollectionType:2.0</r:URN>
          <d:TypeOfModeOfCollection>Measurements and tests</d:TypeOfModeOfCollection>
          <r:Description>
            <r:Content xml:lang="en">Measurements and tests</r:Content>
            <r:Content xml:lang="sv">Mätningar och tester</r:Content>
          </r:Description>
        </d:ModeOfCollection>
      </d:CollectionEvent>
    </d:DataCollection>
    <a:Archive>
      <r:URN>urn:ddi:se.researchdata:snd1065-1.Archive:2.0</r:URN>
      <a:ArchiveSpecific>
        <a:Item>
          <a:Access>
            <r:URN>urn:ddi:se.researchdata:snd1065-1.Archive-ArchiveSpecificType-AccessType:2.0</r:URN>
            <a:TypeOfAccess controlledVocabularyName="info:eu-repo-Access-Terms vocabulary">restrictedAccess</a:TypeOfAccess>
          </a:Access>
          <a:DataFileQuantity>0</a:DataFileQuantity>
        </a:Item>
      </a:ArchiveSpecific>
    </a:Archive>
  </s:StudyUnit>
</ddi:DDIInstance>